PT  - JOURNAL ARTICLE
AU  - Christopher J. Endres
AU  - Jennifer M. Coughlin
AU  - Kenneth L. Gage
AU  - Crystal C. Watkins
AU  - Michael Kassiou
AU  - Martin G. Pomper
TI  - Radiation Dosimetry and Biodistribution of the TSPO Ligand <sup>11</sup>C-DPA-713 in Humans
AID  - 10.2967/jnumed.111.094565
DP  - 2012 Feb 01
TA  - Journal of Nuclear Medicine
PG  - 330--335
VI  - 53
IP  - 2
4099  - http://jnm.snmjournals.org/content/53/2/330.short
4100  - http://jnm.snmjournals.org/content/53/2/330.full
SO  - J Nucl Med2012 Feb 01; 53
AB  - Whole-body PET/CT was used to characterize the radiation dosimetry of 11C-DPA-713, a specific PET ligand for the assessment of translocator protein. Methods: Six healthy control subjects, 3 men and 3 women, underwent whole-body dynamic PET scans after bolus injection of 11C-DPA-713. Subjects were scanned from head to mid thigh with 7 passes performed, with a total PET acquisition of approximately 100 min. Time–activity curves were generated in organs with visible tracer uptake, and tissue residence times were calculated. Whole-body dosimetry was calculated using OLINDA 1.1 software, assuming no voiding. Results: The absorbed dose is highest in the lungs, spleen, kidney, and pancreas. The lungs were determined to be the dose-limiting organ, with an average absorbed dose of 2.01 × 10−2 mSv/MBq (7.43 × 10−2 rem/mCi). On the basis of exposure limits outlined in the U.S. Food and Drug Administration Code of Federal Regulations (21CFR361.1), the single-dose limit for 11C-DPA-713 radiotracer injection is 2,487.6 MBq (67.3 mCi). Conclusion: 11C-DPA-713 has an uptake pattern that is consistent with the biodistribution of translocator protein and yields a dose burden that is comparable to that of other 11C-labeled PET tracers.